person · Reporting owner

Began Marc A

Disclosed activity across 2 companies

Tapewire entity: 24363
SEC CIK: 0001821352

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Axogen, Inc.AXGN · Entity 4297	EVP & General Counsel	August 10, 2026	August 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Axogen, Inc.

Report date August 10, 2026 · Filed August 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	50,135	Ending reported balance After 2026-08-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-10 · Exercise / conversion · Acquired 67,500 · Balance 117,635 Row 2 · 2026-08-10 · Sale · Disposed 67,500 · Balance 50,135 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026. F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2033-03-01	Direct	22,500	Reported balance After 2026-08-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-10 · Exercise / conversion · Disposed 67,500 · Balance 22,500 F3: All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.

F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3: All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABIOMED INC

Report date December 22, 2022 · Filed December 27, 2022

Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-12-22 transaction · row 1 1 source row Row 1 · 2022-12-22 · Disposition to issuer · Disposed 12,237 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $266.39 · Expires 2029-05-30	Direct	0	Reported balance After 2022-12-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-12-22 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $223.90 · Expires 2030-05-29	Direct	0	Reported balance After 2022-12-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-12-22 · Disposition to issuer · Disposed 5,125 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $283.88 · Expires 2031-05-25	Direct	0	Reported balance After 2022-12-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-12-22 · Disposition to issuer · Disposed 2,961 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
Perf ormance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	24,029	Reported balance After 2022-12-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-12-22 · Grant · Acquired 24,029 · Balance 24,029 F5: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
Perf ormance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-12-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-12-22 · Disposition to issuer · Disposed 24,029 · Balance 0 F5: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.

F2: Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time.

F3: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and

F4: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.

F5: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and

F6: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2026 Filed Aug 12, 2026 20:13 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	67,500	$0.00 Strike: $8.16	$0.00	Disclosure SEC source: 0000805928-26-000099 · wk-form4_1786565598.xml · derivative · entry 3 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 67,500 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter. Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC	Axogen, Inc. AXGN · Entity 4297	SaleCommon Stock	67,500	$47.35	$3,195,787.50	Disclosure SEC source: 0000805928-26-000099 · wk-form4_1786565598.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,135 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:13 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionCommon Stock	67,500	$8.16	$550,800.00	Disclosure SEC source: 0000805928-26-000099 · wk-form4_1786565598.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2026 Filed Mar 2, 2026 23:15 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionRestricted Stock Units · Derivative	11,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · derivative · entry 6 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock. F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the RSUs will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4). F7 · derivative.expiration_date: All shares of Axogen, Inc. common stock underlying the RSUs will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4). Read SEC document
March 01, 2026 Filed Mar 2, 2026 23:15 UTC	Axogen, Inc. AXGN · Entity 4297	Tax withholdingCommon Stock	4,427	$30.65	$135,687.55	Disclosure SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 4 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,135 F4 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of RSUs. Read SEC document
March 01, 2026 Filed Mar 2, 2026 23:15 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionCommon Stock	11,250	$0.00	$0.00	Disclosure SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 3 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 1, 2026. Read SEC document
February 26, 2026 Filed Mar 2, 2026 23:15 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	23,000	$0.00	$0.00	Disclosure SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · derivative · entry 5 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the RSUs will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the RSUs will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document
February 26, 2026 Filed Mar 2, 2026 23:15 UTC	Axogen, Inc. AXGN · Entity 4297	Tax withholdingCommon Stock	8,753	$31.90	$279,220.70	Disclosure SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,312 F2 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs"). Read SEC document
February 26, 2026 Filed Mar 2, 2026 23:15 UTC	Axogen, Inc. AXGN · Entity 4297	GrantCommon Stock	33,780	$0.00	$0.00	Disclosure SEC source: 0000805928-26-000042 · wk-form4_1772493346.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,065 F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria. Read SEC document
December 11, 2025 Filed Dec 12, 2025 21:05 UTC	Axogen, Inc. AXGN · Entity 4297	SaleCommon Stock	13,222	$30.00	$396,660.00	Disclosure SEC source: 0000805928-25-000170 · wk-form4_1765573554.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,285 Read SEC document
December 09, 2025 Filed Dec 10, 2025 22:19 UTC	Axogen, Inc. AXGN · Entity 4297	SaleCommon Stock	9,278	$31.21	$289,547.82	Disclosure SEC source: 0000805928-25-000162 · wk-form4_1765405180.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,507 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units on December 4, 2025. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on December 9, 2025 in multiple transactions at $31.208 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 04, 2025 Filed Dec 5, 2025 21:56 UTC	Axogen, Inc. AXGN · Entity 4297	GrantCommon Stock	22,500	$0.00	$0.00	Disclosure SEC source: 0000805928-25-000151 · wk-form4_1764971775.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,785 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document
March 25, 2025 Filed Mar 26, 2025 20:47 UTC	Axogen, Inc. AXGN · Entity 4297	GrantRestricted Stock Units · Derivative	55,000	$0.00	$0.00	Disclosure SEC source: 0000805928-25-000044 · wk-form4_1743022024.xml · derivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document
March 04, 2025 Filed Mar 5, 2025 23:24 UTC	Axogen, Inc. AXGN · Entity 4297	Tax withholdingCommon Stock	5,901	$18.36	$108,342.36	Disclosure SEC source: 0000805928-25-000035 · wk-form4_1741217056.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,285 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 1, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 4, 2025 in multiple transactions at prices ranging from $18.34 to $18.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 01, 2025 Filed Mar 5, 2025 23:24 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionRestricted Stock Units · Derivative	22,500	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000805928-25-000035 · wk-form4_1741217056.xml · derivative · entry 3 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the restricted stock units will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4). F5 · derivative.expiration_date: All shares of Axogen, Inc. common stock underlying the restricted stock units will be fully vested on March 1, 2027 based on a vesting schedule whereby 50% of the aggregate shares vest on March 1, 2025, and an additional 25% of the aggregate shares vest each twelve months thereafter. Vested shares will be delivered to the Reporting Person upon the vesting date. The RSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4). Read SEC document
March 01, 2025 Filed Mar 5, 2025 23:24 UTC	Axogen, Inc. AXGN · Entity 4297	Exercise / conversionCommon Stock	22,500	$0.00	$0.00	Disclosure SEC source: 0000805928-25-000035 · wk-form4_1741217056.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on March 1, 2025. Read SEC document
February 25, 2025 Filed Feb 26, 2025 21:24 UTC	Axogen, Inc. AXGN · Entity 4297	Tax withholdingCommon Stock	814	$16.50	$13,431.00	Disclosure SEC source: 0000805928-25-000019 · wk-form4_1740605048.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,686 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025 in multiple transactions at prices ranging from $16.42 to $17.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
February 22, 2025 Filed Feb 26, 2025 21:24 UTC	Axogen, Inc. AXGN · Entity 4297	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0000805928-25-000019 · wk-form4_1740605048.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document
February 22, 2024 Filed Feb 23, 2024 21:00 UTC	Axogen, Inc. AXGN · Entity 4297	GrantPerformance Stock Units · Derivative	68,600	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003887 · doc4.xml · derivative · entry 1 Began Marc A · CIK 0001821352 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,600 Underlying: Common Stock · 68,600 shares Expires not disclosed F1 · derivative.exercise_price: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number. F1 · derivative.exercise_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number. F1 · derivative.expiration_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number. Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:46 UTC	ABIOMED INC NASD · Entity 121309	Disposition to issuerPerf ormance Stock Units · Derivative	24,029	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001415889-22-013011 · form4-12272022_101212.xml · derivative · entry 6 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,029 shares Expires not disclosed F5 · kind: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · kind: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F5 · price: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · price: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · derivative.exercise_date: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · derivative.expiration_date: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:46 UTC	ABIOMED INC NASD · Entity 121309	GrantPerf ormance Stock Units · Derivative	24,029	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001415889-22-013011 · form4-12272022_101212.xml · derivative · entry 5 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,029 Underlying: Common Stock · 24,029 shares Expires not disclosed F5 · kind: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · kind: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F5 · price: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · price: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · derivative.exercise_date: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) and F6 · derivative.expiration_date: (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:46 UTC	ABIOMED INC NASD · Entity 121309	Disposition to issuerStock Option (Right to Buy) · Derivative	2,961	Not disclosed Strike: $283.88	Not disclosed	Disclosure SEC source: 0001415889-22-013011 · form4-12272022_101212.xml · derivative · entry 4 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,961 shares Expires 2031-05-25 F3 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · kind: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · price: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · derivative.exercise_date: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:46 UTC	ABIOMED INC NASD · Entity 121309	Disposition to issuerStock Option (Right to Buy) · Derivative	5,125	Not disclosed Strike: $223.90	Not disclosed	Disclosure SEC source: 0001415889-22-013011 · form4-12272022_101212.xml · derivative · entry 3 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,125 shares Expires 2030-05-29 F3 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · kind: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · price: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · derivative.exercise_date: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:46 UTC	ABIOMED INC NASD · Entity 121309	Disposition to issuerStock Option (Right to Buy) · Derivative	7,000	Not disclosed Strike: $266.39	Not disclosed	Disclosure SEC source: 0001415889-22-013011 · form4-12272022_101212.xml · derivative · entry 2 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2029-05-30 F3 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · kind: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · price: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; and F4 · derivative.exercise_date: (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document
December 22, 2022 Filed Dec 27, 2022 17:46 UTC	ABIOMED INC NASD · Entity 121309	Disposition to issuerCommon Stock, $0.01 par value	12,237	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-22-013011 · form4-12272022_101212.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · kind: Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time. F1 · price: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · price: Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time. Read SEC document
November 05, 2022 Filed Nov 8, 2022 16:34 UTC	ABIOMED INC NASD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	1,548	$373.99	$578,936.52	Disclosure SEC source: 0001415889-22-011186 · form4-11082022_091107.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,237 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
November 04, 2022 Filed Nov 8, 2022 16:34 UTC	ABIOMED INC NASD · Entity 121309	SaleCommon Stock, $0.01 par value	2,000	$373.71	$747,420.00	Disclosure SEC source: 0001415889-22-011186 · form4-11082022_091107.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,785 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $373.7100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
August 29, 2022 Filed Aug 30, 2022 16:34 UTC	ABIOMED INC NASD · Entity 121309	SaleCommon Stock, $0.01 par value	500	$255.95	$127,975.00	Disclosure SEC source: 0001415889-22-009176 · form4-08302022_010837.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,785 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $259.9500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document
May 29, 2022 Filed May 31, 2022 17:31 UTC	ABIOMED INC NASD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	480	$266.34	$127,843.20	Disclosure SEC source: 0001415889-22-005932 · form4-05312022_020511.xml · nonDerivative · entry 4 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,285 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 29, 2022 Filed May 31, 2022 17:31 UTC	ABIOMED INC NASD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	976	$266.34	$259,947.84	Disclosure SEC source: 0001415889-22-005932 · form4-05312022_020511.xml · nonDerivative · entry 3 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,765 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 29, 2022 Filed May 31, 2022 17:31 UTC	ABIOMED INC NASD · Entity 121309	GrantCommon Stock, $.01 par value	2,200	$0.00	$0.00	Disclosure SEC source: 0001415889-22-005932 · form4-05312022_020511.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,741 F2 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. F2 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. Read SEC document
May 26, 2022 Filed May 31, 2022 17:31 UTC	ABIOMED INC NASD · Entity 121309	GrantCommon Stock, $.01 par value	4,680	$0.00	$0.00	Disclosure SEC source: 0001415889-22-005932 · form4-05312022_020511.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,541 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
May 25, 2022 Filed May 27, 2022 16:09 UTC	ABIOMED INC NASD · Entity 121309	Tax withholdingCommon Stock, $.01 par value	298	$249.19	$74,258.62	Disclosure SEC source: 0001415889-22-005797 · form4-05272022_010551.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,861 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
November 06, 2021 Filed Nov 9, 2021 16:06 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	152	$361.71	$54,979.92	Disclosure SEC source: 0001179110-21-009978 · edgar.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,159 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
November 03, 2021 Filed Nov 5, 2021 16:29 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	1,549	$349.76	$541,778.24	Disclosure SEC source: 0001179110-21-009902 · edgar.xml · nonDerivative · entry 2 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,311 F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
November 03, 2021 Filed Nov 5, 2021 16:29 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock, $0.01 par value	6,975	$0.00	$0.00	Disclosure SEC source: 0001179110-21-009902 · edgar.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,860 F4 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 5, 2020. One half of these restricted stock units vested on November 3, 2021 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second anniversary of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F4 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 5, 2020. One half of these restricted stock units vested on November 3, 2021 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second anniversary of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
July 23, 2021 Filed Jul 26, 2021 17:12 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	106	$323.54	$34,295.24	Disclosure SEC source: 0001179110-21-007660 · edgar.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,885 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 29, 2021 Filed Jun 2, 2021 16:46 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	480	$284.58	$136,598.40	Disclosure SEC source: 0001179110-21-006232 · edgar.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,991 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document
May 25, 2021 Filed May 27, 2021 16:44 UTC	ABIOMED INC ABMD · Entity 121309	GrantStock Option (Right to Buy) · Derivative	2,961	$0.00 Strike: $283.88	$0.00	Disclosure SEC source: 0001179110-21-006012 · edgar.xml · derivative · entry 4 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,961 Underlying: Common Stock · 2,961 shares Expires 2031-05-25 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document
May 25, 2021 Filed May 27, 2021 16:44 UTC	ABIOMED INC ABMD · Entity 121309	GrantCommon Stock, $0.01 par value	2,000	$0.00	$0.00	Disclosure SEC source: 0001179110-21-006012 · edgar.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,471 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25, 2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25, 2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document
November 06, 2020 Filed Nov 10, 2020 16:30 UTC	ABIOMED INC ABMD · Entity 121309	Tax withholdingCommon Stock, $0.01 par value	153	$272.40	$41,677.20	Disclosure SEC source: 0001179110-20-010972 · edgar.xml · nonDerivative · entry 1 Began Marc A · CIK 0001821352 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,471 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.